Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.
Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.
Our cells live ever on the verge of suicide, requiring the close attention of a team of molecules to prevent the cells from pulling the trigger. This self-destructive tendency can be a very good thing, as when dangerous precancerous cells are permitted to kill themselves, but it can also go horribly wrong, destroying brain cells that store memories, for instance. Rockefeller University scientists are parsing this perilous arrangement in ever finer detail in hopes that understanding the basic mechanisms of programmed cell death, or apoptosis, will enable them eventually to manipulate the process to kill the cells we want to kill and protect the ones we don't.
Prostate cancer is one of the most common cancers in America and may lead to more than 32,000 deaths this year. Medical Doctor and cancer expert, Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer.
The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has entered a collaboration with New Jersey based medical technology company BD to evaluate and potentially develop for research and diagnostic use some of the institute's reagents.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B.
Stem cells, the prodigious precursors of all the tissues in our body, can make almost anything, given the right circumstances. Including, unfortunately, cancer. Now research from Rockefeller University shows that having too many stem cells, or stem cells that live for too long, can increase the odds of developing cancer.
Assistant Prof. Patrick C. H. Hsieh of Institute of Nanotechnology and Microsystems Engineering, College of Medicine, National Cheng Kung University (NCKU), Tainan, Taiwan, has led a research team of myocardial regeneration to conduct an experiment on pigs and has proved that by combining self-assembling peptide nanofiber hydrogel with autologous bone marrow stem cell, myocardial protection after acute myocardial infarction, vascular regeneration and heart functions can be improved.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
A calcium sensing protein, STIM1, known to activate store-operated calcium channels has been found to also inhibit voltage-operated calcium channels, according to researchers at Temple University.
Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., and a team of VCU Massey researchers have uncovered the mechanism by which leukemia cells trigger a protective response when exposed to a class of cancer-killing agents known as histone deacetylase inhibitors (HDACIs).
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
Garlic has significant potential for preventing cardiomyopathy, a form of heart disease that is a leading cause of death in people with diabetes, scientists have concluded in a new study. Their report, which also explains why people with diabetes are at high risk for diabetic cardiomyopathy, appears in ACS' bi-weekly Journal of Agricultural and Food Chemistry.
Senesco Technologies, Inc. reported financial results for the 12 months ended June 30, 2010 ("Fiscal 2010").
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).
One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.
In light of Prostate Cancer Awareness month, integrative medicine pioneer and cancer expert Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer. As a well known specialist in the field of integrative prostate cancer therapy, Dr. Eliaz strategically combines ancient and modern healing modalities into a holistic practice of medicine by successfully incorporating the most effective and well researched therapies available in conventional and complementary medicine.
Scientists have discovered that the presence of specific proteins in the blood are indicative of early liver cell damage and can determine the point at which cell death occurred, the type of cell death, and the extent of any damage. This could lead to liver damage being assessed faster and more accurately in the future information which could prove valuable when treating people following drug overdoses.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.